View ValuationBioqual 将来の成長Future 基準チェック /06現在、 Bioqualの成長と収益を予測するのに十分なアナリストの調査がありません。主要情報n/a収益成長率n/aEPS成長率Life Sciences 収益成長17.5%収益成長率n/a将来の株主資本利益率n/aアナリストカバレッジNone最終更新日n/a今後の成長に関する最新情報更新なしすべての更新を表示Recent updatesお知らせ • May 01+ 1 more updateBioqual, Inc. Announces Executive ChangesBIOQUAL, Inc. announces Dr. Mark Lewis will be retiring as President of BIOQUAL effective May 31, 2025, and is succeeded by Dr. Hanne Andersen Elyard, BIOQUAL’s Chief Science Officer. Dr. Lewis will remain as Chairman of the Board of Directors. Dr. Lewis joined BIOQUAL as Senior Scientist in August 2003. He became the Executive Vice President in October 2008 and served in that capacity until he became President and CEO in 2010. Hanne Andersen Elyard received her PhD in microbiology from the Louisiana State University Health Sciences Center in 2000. She was a postdoctoral fellow in the AIDS Vaccine Program, SAIC-Frederick, Inc. from 2001 until 2005. In January 2006 she joined BIOQUAL as a staff scientist, was promoted to Research Director in 2010, promoted to Vice President of Science in 2018 and subsequently she was promoted to Chief Scientific Officer in 2022. She has authored or co-authored more than 105 peer-reviewed scientific publications.お知らせ • Apr 25BIOQUAL Announces Retirement of Mike O'Flaherty from Board, Effective May 1, 2025BIOQUAL, Inc. announced that Mr. Michael P. O’Flaherty will retire from his role as a BIOQUAL Board Member effective May 1, 2025. Mr. O’Flaherty served as the Chief Operating Officer and Secretary of the Corporation until he retired in 2015 at which time he was elected to the BIOQUAL Board. Mr. O’Flaherty is 86 years old and has served as a Director since 2015. His retirement is not connected to any disagreements with the Board’s policies or practices.お知らせ • Jan 15BIOQUAL, Inc. Announces Changes to Board of DirectorsBIOQUAL, Inc. announced that Mr. Charles Francisco retired from his role as a BIOQUAL Board Member effective December 31, 2024. Mr. Francisco is 85 years old and has served as a director since 1992. His retirement is not connected to any disagreements with the Board’s policies or practices. Additionally, on December 31, 2024, BIOQUAL appointed Ms. Amy Johnston to the BIOQUAL Board of Directors. Ms. Johnston will replace Mr. Francisco on the Board, thus, the number of directors will not change. Ms. Johnston has been working with and managing companies in the healthcare and biotech industries for over thirty years. She holds a Bachelor of Arts in Government and English (dual degree) and a Master of Arts degree in Secondary English Education from the College of William and Mary in Virginia. Among her career accomplishments: Led cross-functional teams to build commercial biotech teams and strategies while ensuring compliance with FDA regulations, Provided critical support in pre-launch and post-launch efforts for a Hepatitis C compound, achieving $1B in sales in the first year on the commercial market, Collaborated with media and advertising agencies, managed market teams, Key Opinion Leaders, and patient advocacy groups to educate both the medical community and the patients, By revising the strategy and operating model of a design/build employee-owned utility company, Amy and her business partner increased revenue from $10 million to $25 million even during the economically unstable period of the pandemic. Amy led the team that successfully valued and negotiated the sale of her interest in the company in 2022.お知らせ • Oct 01Bioqual, Inc. Declares Dividend, Payable on October 28, 2024Bioqual, Inc.’s board of directors has declared a dividend of $0.50 per share for shareholders of record on October 7, 2024, payable on October 28, 2024.お知らせ • Sep 15Bioqual, Inc. Announces Reduction in WorkforceBIOQUAL, Inc. announced a reduction in workforce (RIF) of approximately 10% of its employees effective September 9, 2024. The RIF was a necessary cost-cutting measure due to the decrease in revenue and profitability that BIOQUAL has experienced in the last year. In a post-COVID-19 environment, the Company has seen a significant drop in the demand for their services due to the development of COVID-19 vaccines and therapeutics and needed to realign its cost structure accordingly. BIOQUAL does not expect the RIF to impact the current services it provides or to hamper its business prospects for the future.お知らせ • Oct 06Bioqual, Inc. Appoints Charles (Chris) C. Kirk, Jr., CPA as Chief Financial OfficerBIOQUAL, Inc. announced promotion of Mr. Charles (Chris) C. Kirk, Jr., CPA. to the position of chief financial officer. Mr. Kirk has over 25 years of experience in leadership roles in finance and accounting departments for both Government contracting and services-oriented companies as well as in the public accounting sector. Mr. Kirk has served as Director of Finance and Accounting for the company over the past year and has a degree in Accounting/Finance from the University of Maryland. In his role as Chief Financial Officer, Mr. Kirk will lead the Accounting/Finance team at BIOQUAL and will join the company's executive leadership team.お知らせ • Sep 28BIOQUAL Declares Dividend, Payable on October 27, 2022BIOQUAL announced that its Board of Directors has declared a dividend of $1.00 per share for shareholders of record on October 6, 2022, payable on October 27, 2022.お知らせ • May 10+ 2 more updatesBIOQUAL, Inc. Announces Retirement of Dave Newcomer as Chief Financial Officer, Effective June 3, 2022BIOQUAL, Inc. announced that Dave Newcomer will retire from his role as Chief Financial Officer effective June 3, 2022. Newcomer will remain in his current position until then to support with the transition of his responsibilities to his successor. Newcomer’s position will be filled by Charles (Chris) C. Kirk, Jr., CPA. Kirk has over 25 years of experience in leadership roles in finance and accounting departments for both government contracting and services oriented companies as well as in the public accounting sector. Kirk has served as Director of Finance and Accounting for BIOQUAL over the past year.お知らせ • Sep 22Bioqual, Inc. Announces Publication of an Investigational COVID-19 Vaccine CandidateBioqual, Inc. announced that Beth Israel Deaconess Medical Center immunologist Dan H. Barouch and colleagues, including members of the staff at BIOQUAL, showed in recently published previous work that a candidate COVID-19 vaccine raised neutralizing antibodies that robustly protected non-human primates against SARS-CoV-2, the virus that causes COVID-19. In new research published September 3, 2020 in Nature Medicine, Barouch and colleagues demonstrated that the optimal vaccine elicited robust immune response in Syrian golden hamsters and prevented severe clinical disease — including weight loss, pneumonia, and death. The vaccine — developed through a collaboration between BIDMC and Janssen Pharmaceutical Companies of Johnson & Johnson — uses a common cold virus, called adenovirus serotype 26 (Ad26), to deliver the SARS-CoV-2 spike protein into host cells, where it stimulates the body to raise immune responses against the coronavirus. In the current study, the researchers immunized Syrian golden hamsters with a single injection of the Ad26-based SARS-CoV-2 vaccine, which induced neutralizing antibodies in all animals. Four weeks later, the animals were exposed to a high dose of SARS-CoV-2. Vaccinated animals lost less weight and had less virus in their lungs and other organs than unvaccinated control animals. Vaccinated animals also demonstrated lower mortality. Moreover, the researchers found that neutralizing antibody responses were inversely correlated with weight loss and viral loads in respiratory tissues. Ad26.COV2.S is currently being evaluated in clinical studies to establish the performance of the vaccine candidate in humans. In July 2020, investigators at Janssen, Beth Israel Deaconess Medical Center, and other institutions initiated a first-in-human Phase 1/2 clinical trial of the Ad26.COV2.S vaccine in healthy volunteers. Pending clinical trial out-comes, the Ad26.COV2.S vaccine is on track to start a phase 3 efficacy trial in up to 60,000 participants in September 2020. このセクションでは通常、投資家が会社の利益創出能力を理解する一助となるよう、プロのアナリストのコンセンサス予想に基づく収益と利益の成長予測を提示する。しかし、Bioqual は十分な過去のデータを提供しておらず、アナリストの予測もないため、過去のデータを外挿したり、アナリストの予測を使用しても、その将来の収益を確実に算出することはできません。 シンプリー・ウォール・ストリートがカバーする企業の97%は過去の財務データを持っているため、これはかなり稀な状況です。 業績と収益の成長予測OTCPK:BIOQ - アナリストの将来予測と過去の財務データ ( )USD Millions日付収益収益フリー・キャッシュフロー営業活動によるキャッシュ平均アナリスト数2/28/202642-166N/A11/30/202547055N/A8/31/202547-155N/A5/31/202549-133N/A2/28/202549-201N/A11/30/202450-322N/A8/31/202455-189N/A5/31/202459099N/A2/29/202463189N/A11/30/2023620910N/A8/31/202362057N/A5/31/202363168N/A2/28/202365335N/A11/30/2022685-30N/A8/31/2022665-5-1N/A5/31/2022665-50N/A2/28/2022645-24N/A11/30/2021606-25N/A8/31/202158628N/A5/31/2021586-22N/A2/28/2021555-40N/A11/30/202054525N/A8/31/2020515-21N/A5/31/202046424N/A2/29/202044424N/A11/30/2019434N/A0N/A8/31/2019404N/A1N/A5/31/2019393N/A2N/A2/28/2019383N/A2N/A11/30/2018363N/A3N/A8/31/2018374N/A5N/A5/31/2018364N/A4N/A2/28/2018353N/A5N/A11/30/2017363N/A5N/A8/31/2017364N/A3N/A5/31/2017374N/A5N/A2/28/2017374N/AN/AN/A11/30/2016374N/AN/AN/A8/31/2016364N/A5N/A5/31/2016333N/A3N/A2/29/2016312N/A4N/A11/30/2015292N/A2N/A8/31/2015292N/A1N/A5/31/2015292N/A2N/Aもっと見るアナリストによる今後の成長予測収入対貯蓄率: BIOQの予測収益成長が 貯蓄率 ( 3.5% ) を上回っているかどうかを判断するにはデータが不十分です。収益対市場: BIOQの収益がUS市場よりも速く成長すると予測されるかどうかを判断するにはデータが不十分です高成長収益: BIOQの収益が今後 3 年間で 大幅に 増加すると予想されるかどうかを判断するにはデータが不十分です。収益対市場: BIOQの収益がUS市場よりも速く成長すると予測されるかどうかを判断するにはデータが不十分です。高い収益成長: BIOQの収益が年間20%よりも速く成長すると予測されるかどうかを判断するにはデータが不十分です。一株当たり利益成長率予想将来の株主資本利益率将来のROE: BIOQの 自己資本利益率 が 3 年後に高くなると予測されるかどうかを判断するにはデータが不十分です成長企業の発掘7D1Y7D1Y7D1YPharmaceuticals-biotech 業界の高成長企業。View Past Performance企業分析と財務データの現状データ最終更新日（UTC時間）企業分析2026/05/15 13:13終値2026/05/07 00:00収益2026/02/28年間収益2025/05/31データソース企業分析に使用したデータはS&P Global Market Intelligence LLC のものです。本レポートを作成するための分析モデルでは、以下のデータを使用しています。データは正規化されているため、ソースが利用可能になるまでに時間がかかる場合があります。パッケージデータタイムフレーム米国ソース例会社財務10年損益計算書キャッシュ・フロー計算書貸借対照表SECフォーム10-KSECフォーム10-Qアナリストのコンセンサス予想+プラス3年予想財務アナリストの目標株価アナリストリサーチレポートBlue Matrix市場価格30年株価配当、分割、措置ICEマーケットデータSECフォームS-1所有権10年トップ株主インサイダー取引SECフォーム4SECフォーム13Dマネジメント10年リーダーシップ・チーム取締役会SECフォーム10-KSECフォームDEF 14A主な進展10年会社からのお知らせSECフォーム8-K* 米国証券を対象とした例であり、非米国証券については、同等の規制書式および情報源を使用。特に断りのない限り、すべての財務データは1年ごとの期間に基づいていますが、四半期ごとに更新されます。これは、TTM（Trailing Twelve Month）またはLTM（Last Twelve Month）データとして知られています。詳細はこちら。分析モデルとスノーフレーク本レポートを生成するために使用した分析モデルの詳細は当社のGithubページでご覧いただけます。また、レポートの使用方法に関するガイドやYoutubeのチュートリアルも掲載しています。シンプリー・ウォールストリート分析モデルを設計・構築した世界トップクラスのチームについてご紹介します。業界およびセクターの指標私たちの業界とセクションの指標は、Simply Wall Stによって6時間ごとに計算されます。アナリスト筋Bioqual, Inc. 0 これらのアナリストのうち、弊社レポートのインプットとして使用した売上高または利益の予想を提出したのは、 。アナリストの投稿は一日中更新されます。0
お知らせ • May 01+ 1 more updateBioqual, Inc. Announces Executive ChangesBIOQUAL, Inc. announces Dr. Mark Lewis will be retiring as President of BIOQUAL effective May 31, 2025, and is succeeded by Dr. Hanne Andersen Elyard, BIOQUAL’s Chief Science Officer. Dr. Lewis will remain as Chairman of the Board of Directors. Dr. Lewis joined BIOQUAL as Senior Scientist in August 2003. He became the Executive Vice President in October 2008 and served in that capacity until he became President and CEO in 2010. Hanne Andersen Elyard received her PhD in microbiology from the Louisiana State University Health Sciences Center in 2000. She was a postdoctoral fellow in the AIDS Vaccine Program, SAIC-Frederick, Inc. from 2001 until 2005. In January 2006 she joined BIOQUAL as a staff scientist, was promoted to Research Director in 2010, promoted to Vice President of Science in 2018 and subsequently she was promoted to Chief Scientific Officer in 2022. She has authored or co-authored more than 105 peer-reviewed scientific publications.
お知らせ • Apr 25BIOQUAL Announces Retirement of Mike O'Flaherty from Board, Effective May 1, 2025BIOQUAL, Inc. announced that Mr. Michael P. O’Flaherty will retire from his role as a BIOQUAL Board Member effective May 1, 2025. Mr. O’Flaherty served as the Chief Operating Officer and Secretary of the Corporation until he retired in 2015 at which time he was elected to the BIOQUAL Board. Mr. O’Flaherty is 86 years old and has served as a Director since 2015. His retirement is not connected to any disagreements with the Board’s policies or practices.
お知らせ • Jan 15BIOQUAL, Inc. Announces Changes to Board of DirectorsBIOQUAL, Inc. announced that Mr. Charles Francisco retired from his role as a BIOQUAL Board Member effective December 31, 2024. Mr. Francisco is 85 years old and has served as a director since 1992. His retirement is not connected to any disagreements with the Board’s policies or practices. Additionally, on December 31, 2024, BIOQUAL appointed Ms. Amy Johnston to the BIOQUAL Board of Directors. Ms. Johnston will replace Mr. Francisco on the Board, thus, the number of directors will not change. Ms. Johnston has been working with and managing companies in the healthcare and biotech industries for over thirty years. She holds a Bachelor of Arts in Government and English (dual degree) and a Master of Arts degree in Secondary English Education from the College of William and Mary in Virginia. Among her career accomplishments: Led cross-functional teams to build commercial biotech teams and strategies while ensuring compliance with FDA regulations, Provided critical support in pre-launch and post-launch efforts for a Hepatitis C compound, achieving $1B in sales in the first year on the commercial market, Collaborated with media and advertising agencies, managed market teams, Key Opinion Leaders, and patient advocacy groups to educate both the medical community and the patients, By revising the strategy and operating model of a design/build employee-owned utility company, Amy and her business partner increased revenue from $10 million to $25 million even during the economically unstable period of the pandemic. Amy led the team that successfully valued and negotiated the sale of her interest in the company in 2022.
お知らせ • Oct 01Bioqual, Inc. Declares Dividend, Payable on October 28, 2024Bioqual, Inc.’s board of directors has declared a dividend of $0.50 per share for shareholders of record on October 7, 2024, payable on October 28, 2024.
お知らせ • Sep 15Bioqual, Inc. Announces Reduction in WorkforceBIOQUAL, Inc. announced a reduction in workforce (RIF) of approximately 10% of its employees effective September 9, 2024. The RIF was a necessary cost-cutting measure due to the decrease in revenue and profitability that BIOQUAL has experienced in the last year. In a post-COVID-19 environment, the Company has seen a significant drop in the demand for their services due to the development of COVID-19 vaccines and therapeutics and needed to realign its cost structure accordingly. BIOQUAL does not expect the RIF to impact the current services it provides or to hamper its business prospects for the future.
お知らせ • Oct 06Bioqual, Inc. Appoints Charles (Chris) C. Kirk, Jr., CPA as Chief Financial OfficerBIOQUAL, Inc. announced promotion of Mr. Charles (Chris) C. Kirk, Jr., CPA. to the position of chief financial officer. Mr. Kirk has over 25 years of experience in leadership roles in finance and accounting departments for both Government contracting and services-oriented companies as well as in the public accounting sector. Mr. Kirk has served as Director of Finance and Accounting for the company over the past year and has a degree in Accounting/Finance from the University of Maryland. In his role as Chief Financial Officer, Mr. Kirk will lead the Accounting/Finance team at BIOQUAL and will join the company's executive leadership team.
お知らせ • Sep 28BIOQUAL Declares Dividend, Payable on October 27, 2022BIOQUAL announced that its Board of Directors has declared a dividend of $1.00 per share for shareholders of record on October 6, 2022, payable on October 27, 2022.
お知らせ • May 10+ 2 more updatesBIOQUAL, Inc. Announces Retirement of Dave Newcomer as Chief Financial Officer, Effective June 3, 2022BIOQUAL, Inc. announced that Dave Newcomer will retire from his role as Chief Financial Officer effective June 3, 2022. Newcomer will remain in his current position until then to support with the transition of his responsibilities to his successor. Newcomer’s position will be filled by Charles (Chris) C. Kirk, Jr., CPA. Kirk has over 25 years of experience in leadership roles in finance and accounting departments for both government contracting and services oriented companies as well as in the public accounting sector. Kirk has served as Director of Finance and Accounting for BIOQUAL over the past year.
お知らせ • Sep 22Bioqual, Inc. Announces Publication of an Investigational COVID-19 Vaccine CandidateBioqual, Inc. announced that Beth Israel Deaconess Medical Center immunologist Dan H. Barouch and colleagues, including members of the staff at BIOQUAL, showed in recently published previous work that a candidate COVID-19 vaccine raised neutralizing antibodies that robustly protected non-human primates against SARS-CoV-2, the virus that causes COVID-19. In new research published September 3, 2020 in Nature Medicine, Barouch and colleagues demonstrated that the optimal vaccine elicited robust immune response in Syrian golden hamsters and prevented severe clinical disease — including weight loss, pneumonia, and death. The vaccine — developed through a collaboration between BIDMC and Janssen Pharmaceutical Companies of Johnson & Johnson — uses a common cold virus, called adenovirus serotype 26 (Ad26), to deliver the SARS-CoV-2 spike protein into host cells, where it stimulates the body to raise immune responses against the coronavirus. In the current study, the researchers immunized Syrian golden hamsters with a single injection of the Ad26-based SARS-CoV-2 vaccine, which induced neutralizing antibodies in all animals. Four weeks later, the animals were exposed to a high dose of SARS-CoV-2. Vaccinated animals lost less weight and had less virus in their lungs and other organs than unvaccinated control animals. Vaccinated animals also demonstrated lower mortality. Moreover, the researchers found that neutralizing antibody responses were inversely correlated with weight loss and viral loads in respiratory tissues. Ad26.COV2.S is currently being evaluated in clinical studies to establish the performance of the vaccine candidate in humans. In July 2020, investigators at Janssen, Beth Israel Deaconess Medical Center, and other institutions initiated a first-in-human Phase 1/2 clinical trial of the Ad26.COV2.S vaccine in healthy volunteers. Pending clinical trial out-comes, the Ad26.COV2.S vaccine is on track to start a phase 3 efficacy trial in up to 60,000 participants in September 2020.